Tandem Diabetes Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025

Reuters

20 May

<a href="https://laohu8.com/S/TNDM">Tandem Diabetes</a> Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025

Tandem Diabetes Care Inc. has announced that it received CE mark approval for its Tandem Mobi insulin delivery system equipped with Control-IQ+ technology on May 16, 2025. This regulatory milestone allows the company to advance its plans for entering the European markets. Tandem Diabetes Care Inc. is now focused on pursuing further regulatory and pre-commercial steps, including securing in-country registrations and reimbursement across EU markets, with the aim of commencing commercial launches by the end of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001438133-25-000091), on May 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2536386613"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536386613\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2536386613?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536386613","market":"nz","top_or_hot":-1,"title":"Tandem Diabetes Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TNDM\">Tandem Diabetes</a> Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tandem Diabetes Care Inc. has announced that it received CE mark approval for its Tandem Mobi insulin delivery system equipped with Control-IQ+ technology on May 16, 2025. This regulatory milestone allows the company to advance its plans for entering the European markets. Tandem Diabetes Care Inc. is now focused on pursuing further regulatory and pre-commercial steps, including securing in-country registrations and reimbursement across EU markets, with the aim of commencing commercial launches by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001438133-25-000091), on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tandem Diabetes Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTandem Diabetes Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-20 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TNDM\">Tandem Diabetes</a> Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tandem Diabetes Care Inc. has announced that it received CE mark approval for its Tandem Mobi insulin delivery system equipped with Control-IQ+ technology on May 16, 2025. This regulatory milestone allows the company to advance its plans for entering the European markets. Tandem Diabetes Care Inc. is now focused on pursuing further regulatory and pre-commercial steps, including securing in-country registrations and reimbursement across EU markets, with the aim of commencing commercial launches by the end of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001438133-25-000091), on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL5WbX7h:1","article_id":"2536386613","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536386613","pubTimestamp":1747735279,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tandem Diabetes Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025. Tandem Diabetes Care Inc. has announced that it received CE mark approval for its Tandem Mobi insulin delivery system equipped with Control-IQ+ technology on May 16, 2025. This regulatory milestone allows the company to advance its plans for entering the European markets. Tandem Diabetes Care Inc. is now focused on pursuing further regulatory and pre-commercial steps, including securing in-country registrations and reimbursement across EU markets, with the aim of commencing commercial launches by the end of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Tandem Diabetes Care Inc.采用Control-IQ+技术的Tandem Mobi胰岛素输送系统获得CE标志批准，计划于2025年底在欧盟推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":0.9},"content_text":"Tandem Diabetes Care Inc. Receives CE Mark Approval for Tandem Mobi Insulin Delivery System with Control-IQ+ Technology, Plans EU Launch by End of 2025\n    \n\n        Tandem Diabetes Care Inc. has announced that it received CE mark approval for its Tandem Mobi insulin delivery system equipped with Control-IQ+ technology on May 16, 2025. This regulatory milestone allows the company to advance its plans for entering the European markets. Tandem Diabetes Care Inc. is now focused on pursuing further regulatory and pre-commercial steps, including securing in-country registrations and reimbursement across EU markets, with the aim of commencing commercial launches by the end of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001438133-25-000091), on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}